Oak Thistle LLC Purchases Shares of 90,615 Kenvue Inc. $KVUE

Oak Thistle LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 90,615 shares of the company’s stock, valued at approximately $1,563,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KVUE. Salomon & Ludwin LLC bought a new stake in Kenvue in the third quarter valued at about $25,000. NBT Bank N A NY raised its position in Kenvue by 180.3% in the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC lifted its stake in Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the period. Golden State Wealth Management LLC lifted its stake in Kenvue by 150.1% during the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after purchasing an additional 1,190 shares during the period. Finally, Trust Co. of Vermont boosted its holdings in Kenvue by 50.9% during the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

NYSE KVUE opened at $17.33 on Thursday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The company has a 50 day moving average of $17.96 and a 200-day moving average of $17.06. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The firm has a market cap of $33.22 billion, a price-to-earnings ratio of 22.51, a PEG ratio of 3.89 and a beta of 0.61.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same period in the prior year, the company earned $0.26 EPS. Kenvue’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 107.79%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KVUE. Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Friday, March 6th. UBS Group decreased their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday. Citigroup upped their price target on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group increased their price objective on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $19.50.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.